Lineage Cell Therapeutics (LCTX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$467.8 million.
- Lineage Cell Therapeutics' Retained Earnings fell 1690.61% to -$467.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$467.8 million, marking a year-over-year decrease of 1690.61%. This contributed to the annual value of -$403.5 million for FY2024, which is 483.53% down from last year.
- According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Retained Earnings is -$467.8 million, which was down 1690.61% from -$438.1 million recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' Retained Earnings registered a high of -$295.5 million during Q1 2021, and its lowest value of -$467.8 million during Q3 2025.
- Moreover, its 5-year median value for Retained Earnings was -$373.0 million (2023), whereas its average is -$372.0 million.
- Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 405.33% in 2021, then plummeted by 1690.61% in 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Retained Earnings (Quarter) stood at -$337.1 million in 2021, then decreased by 7.79% to -$363.4 million in 2022, then decreased by 5.91% to -$384.9 million in 2023, then decreased by 4.84% to -$403.5 million in 2024, then fell by 15.96% to -$467.8 million in 2025.
- Its Retained Earnings stands at -$467.8 million for Q3 2025, versus -$438.1 million for Q2 2025 and -$407.6 million for Q1 2025.